[Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].
Prospective studies that included 48 postmenopausal women on hormonal replacement therapy (transdermal estradiol and medroxyprogesterone acetate orally) was performed. Plasma activity of plasminogen activator inhibitor (PAI-1), levels of fibrinogen and serum lipids profile was measured before, after 6 and 12 months of continuous treatment. Plasma activity of PAI-1 showed significant decrease after 6 month of therapy. Plasma fibrinogen concentration significantly decreased (p < 0.05) after 12 months of treatment (271.27 +/- 71.08 vs. 238.33 +/- 34.48 mg/dl).